and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address ...

and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address ...

Investors with a lot of money to spend have taken a bullish stance on Eli ... Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin ...

and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own ...

Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is investing billions of dollars to scale manufacturing efforts as demand for ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target remains the same with $1,100.00. Discover the latest ...

Eli Lilly and Company will establish a new global capability centre in Hyderabad and recruit more than 1,000 highly skilled team members to strengthen its digital strategy and service delivery.